$LLY

4 theses
bullish 75%neutral 0%bearish 25%
Avg return (6m)
+12.9%
Win rate (6m)
0% (1 resolved)

Past performance does not predict future results. Informational only, not investment advice.

Recent theses

Prices as of Oct 19, 4:30 PM ET
$LLYr/ValueInvestingStock Analysisbullish
u/JoeInOR · 62d ago14 prior · 100% at 3mo
“Not a position but I watch it closely.”

I built a new metric called Y220. Given a company's true FCF yield today and its 3-year revenue CAGR, how long until it reaches 20% yield?

LLY passes the Y220 screen despite failing the current yield test, with parabolic revenue growth and aggressive share retirement offsetting valuation concerns; early GLP-1 innings offer durability questions but compelling optionality.

At post $1,225.73Now $1,240.34+1.2% since postedas of Oct 19, 4:30 PM ET
1d+4.5%
3d+2.4%
1w+0.6%
1m-6.0%
3m—
6m—
1y—
original post →
$LLYr/ValueInvestingStock Analysisbullish
u/Icy_Abbreviations167 · 75d ago6 prior · 20% at 3mo

Eli Lilly’s GLP-1 machine is still running hot

Eli Lilly's GLP-1 franchise (Mounjaro and Zepbound) delivered strong Q2 results with 48% revenue growth and 32% non-GAAP net income growth, significantly beating expectations. The company raised full-year guidance and has an active pipeline with completed Phase 3 data for retatrutide and FDA submissions, supporting sustained upside.

At post $1,168.19Now $1,240.34+6.2% since postedas of Oct 19, 4:30 PM ET
1d+1.9%
3d+1.4%
1w+4.3%
1m-1.6%
3m—
6m—
1y—
original post →
$LLYr/wallstreetbetsGainbullish
u/trsx5 · 155d ago2 prior · 33% at 3mo
“I'm still in $LLY”

After 4 years.. i did it. +107K (realized) YTD.

Author's biggest winner YTD and states they remain positioned in LLY. The stock was one of their major plays contributing to the +107K realized gain, and they emphasize concentration builds wealth.

At post $986.68Now $1,240.34+25.7% since postedas of Oct 19, 4:30 PM ET
1d—
3d+3.1%
1w+7.8%
1m+13.6%
3m+19.6%
6m—
1y—
original post →
$LLYr/ValueInvestingDiscussionbearish
u/SelfMastery__ · 368d ago3 prior · 25% at 3mo

Trump says the prices of GLP-1s will come down “pretty fast”

Trump's announcement that his administration will negotiate lower GLP-1 prices threatens Eli Lilly's profitability and margin structure. The immediate post-market decline reflects market concern about pricing pressure on the company's blockbuster weight loss drug franchise.

At post $814.24Now $1,240.34+52.3% since postedas of Oct 19, 4:30 PM ET
1d-2.0%
3d-2.0%
1w+0.2%
1m+25.3%
3m+31.2%
6m+12.9%
1y+54.4%
original post →

End of results.